Jan. 28-29

Mountain View, CA

Receive PMWC updates & offers by email

First:
Last:
Email:

Track 2

Established Company, Clinician, Researcher and Government Presentations

Overview

Track 2 showcases established company, clinician, and researcher presentations and exhibitions on the latest products and services enabling practical applications of Personalized Medicine.

Process

1Submit 

Stage 1: Submit


Presenter Criteria

Public or large-cap private companies and institutions:

  • Therapeutics
  • Diagnostics
  • Healthtech
  • Advocacy

 


Submit
2Evaluation

Stage 2: Evaluation


Evaluation is made by a Screening Committee that determines whether the proposed topic contributes to the advancement and/or adoption of personalized medicine.

 

Applicants notified within ~one week

3Registration

Stage 3: Registration


Registration Benefits

 

  • 15 min podium presentation (parallel track)
  • 2 admissions (value $3000)
  • Exhibition 6x2.5 (upgrades available in registration form)
  • Speaker, talk title & bio on Speakers web page
  • Logo and link on exhibition map

 

Fee: $6000


Register here

Current Presenters

AssureRx Asuragen CardioDx Cedars-Sinai Heart Institute Coriell Institute deCode genetics Erasmus Medical Center, Netherlands IBM Molecular Health Ariosa OncoMed Pharmaceuticals PamLab Pfizer Plexxikon RocheDx Selventa Sequenom UCSF Helen Diller Whitehead Institute Xconomy

Past Presenters

Kaiser

Auxogyn, Inc.

Country: U.S.A.

Focus area: Improving the percentage of in vitro fertilization procedures that result in a live birth.

Nodality

Nodality, Inc.

Country: U.S.A.

Focus area: Cancer and autoimmune disease predictive tests.

QuantaLife QuantaLife QuantaLife
Quantalife

Quantalife, Inc.

Country: U.S.A.

Focus area: Polymerase Chain Reaction (PCR) systems

Acquired by Bio-Rad for $162M 3 years after starting

AIT AIT Agilent Technologies

Applied Immune Technologies Ltd.

Country: Israel

Focus area: T-Cell Receptor-Like (TCRL) antibodies

DVS Sciences
DVS Sciences

DVS Sciences

DVS Sciences manufactures and globally distributes novel bioanalytical solutions for use in biomarker discovery, biological research and potential future use in clinical applications. The patented multi-parameter technology comprises a high-throughput mass cytometer for quantitative individual cell analysis, CyTOF, and a suite of MAXPAR reagents.

Epizyme
Epizyme

Epizyme

Epizyme discovers and develops small molecule histone methyltransferase (HMT) inhibitors, a new class of personalized therapeutics for the treatment of genetically-defined cancer patients based on breakthroughs in the field of epigenetics.

Genia Technology
Genia Technology

Genia Technology

Genia Technology core technology is the biological nanopore, which reduces the price of sequencing and increases speed, accuracy, and sensitivity by moving away from enzyme-based sequencing methods and optical detection.

Integrated Diagnostics
Integrated Diagnostics

Integrated Diagnostics

Integrated Diagnostics is creating large-scale, blood-based molecular diagnostics that leverage advances in proteomics and genomics to detect disease at its earliest stage.

NextBio
NextBio

NextBio

NextBio has a mission is to integrate the world's genomic data, enabling researchers and clinicians to develop unprecedented biomedical insights and improve human health. NextBio has built a powerful platform to aggregate, correlate and interpret world's collections of private and public genomic data.

Recombinant
Recombinant Data

Recombinant Data

Recombinant Data offers life sciences software solutions for translational research. Their standard software packages are toolkits and frameworks for establishing translational research data warehouses and the analytics utilities to maximize use of those data assets.

Telome Health
Telome Health

Telome Health

Telome Health technology will analyze tissue samples to provide customers with accurate and reliable analyses of telomere biology. This data will be generated by research scientists for the research market, and by qualified personnel in a CLIA certified laboratory for the regulated consumer and pharmaceutical markets.

Vision Gate
Vision Gate

Vision Gate

Vision Gate aims to dramatically improve patient health with the world's first, non-invasive, diagnostic test for early lung cancer detection: LuCED™. Additional diagnostic tests for gastroesophageal reflux disease (GERD), bladder cancer and other cancer types will follow.

Partial List of Past Companies and Institutional participants

 

Agilent Technologies
Albert Einstein Medical School
Amgen
Ancestry.com
Applied Materials
AstraZeneca
Bayer HealthCare
Baylor College of Medicine
Beckman Coulter
Berkeley HeartLab Inc.
Biogen Idec
Blue Cross Blue Shield
Bosch
CTCA
Cedars-Sinai Heart Institute
Cleveland Clinic
Children's Hospital, Los Angeles
Coriell Institute
UCLA
Dell Heathcare Life Sciences
Deloitte
Duke University
El Camino Hospital
FDA
Frost & Sullivan
Geisinger Ventures
Gilead Sciences, Inc.
Goldman Sachs
Good Samaritan Hospital
Google
Harvard Medical School
Hitachi Chemical Research Center
IBM
IDEO
Ignite Institute
Illumina
INdivumed GmbH
Inova Health System
Institute for Systems Biology
Intel
Johns Hopkins University
Johnson & Johnson
JDRF
Knight Diagnostic Labs
Lam Research
Lazard
Life Technologies
Lucile Packard Children's Hospital
Mass. General Hospital
Mayo Clinic
McKesson
MDVIP
Medco Health Solutions
Merck Millipore
Microsoft
Milken Institute
Mizuho Institute
Moffitt Cancer Center
Morgan Stanley
Mount Sinai School of Medicine
NASA Ames Research Center
National Cancer Institute
Navigenics
NIST
Novartis
NVIDIA Foundation
Oak Ridge National Laboratory
OHSU Medical Center
Pacific Biosciences
Palo Alto Medical Center
Perkin Elmer
Philip Morris
PricewaterhouseCoopers
Quest Diagnostics
Quintiles
RIKEN Genesis
SAP
Shire
Siemens HC Diagnostics
TGen
Thermo Fisher Scientific
US Dept. of Commerce
UC Berkeley
UC Davis
UC San Francisco
University of Utah
Vanderbilt University
Waters Clinical

 

    This entire site is licensed under Creative Commons Attribution-NoDerivs.   |   © Copyright PMWC International